Intellia Therapeutics, Inc. (NTLA) Given a $42.00 Price Target at Jefferies Group LLC
Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been given a $42.00 price objective by equities researchers at Jefferies Group LLC in a research report issued to clients and investors on Tuesday. The firm currently has a “buy” rating on the stock. Jefferies Group LLC’s price target suggests a potential upside of 34.96% from the stock’s previous close.
Several other research analysts have also commented on NTLA. Zacks Investment Research raised shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, October 4th. Cann reaffirmed a “hold” rating on shares of Intellia Therapeutics in a report on Tuesday, August 1st. Chardan Capital reaffirmed a “buy” rating and issued a $20.00 price target (up from $19.00) on shares of Intellia Therapeutics in a report on Wednesday, August 2nd. Leerink Swann lifted their price target on shares of Intellia Therapeutics from $29.00 to $37.00 and gave the company an “outperform” rating in a report on Tuesday. They noted that the move was a valuation call. Finally, TheStreet raised shares of Intellia Therapeutics from a “d+” rating to a “c-” rating in a report on Thursday, July 6th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $29.50.
Shares of Intellia Therapeutics (NASDAQ NTLA) traded up 8.89% during midday trading on Tuesday, hitting $31.12. 771,012 shares of the stock traded hands. The firm has a 50-day moving average price of $26.31 and a 200 day moving average price of $26.31. The stock’s market cap is $1.12 billion. Intellia Therapeutics has a one year low of $10.83 and a one year high of $33.34.
Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Tuesday, October 31st. The company reported ($0.44) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.06. Intellia Therapeutics had a negative net margin of 204.48% and a negative return on equity of 22.70%. The business had revenue of $7.30 million during the quarter, compared to analyst estimates of $5.83 million. During the same period in the previous year, the business posted ($0.22) EPS. The company’s quarterly revenue was up 49.0% on a year-over-year basis. Analysts anticipate that Intellia Therapeutics will post ($1.78) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/31/intellia-therapeutics-inc-ntla-given-a-42-00-price-target-at-jefferies-group-llc.html.
A number of institutional investors have recently bought and sold shares of the business. Moloney Securities Asset Management LLC acquired a new position in Intellia Therapeutics during the 3rd quarter valued at about $306,000. Dynamic Technology Lab Private Ltd acquired a new position in Intellia Therapeutics during the 2nd quarter valued at about $167,000. California State Teachers Retirement System boosted its stake in Intellia Therapeutics by 79.0% during the 2nd quarter. California State Teachers Retirement System now owns 25,143 shares of the company’s stock valued at $402,000 after purchasing an additional 11,100 shares during the period. The Manufacturers Life Insurance Company boosted its stake in Intellia Therapeutics by 451.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,224 shares of the company’s stock valued at $212,000 after purchasing an additional 10,825 shares during the period. Finally, State Street Corp boosted its stake in Intellia Therapeutics by 52.0% during the 2nd quarter. State Street Corp now owns 164,798 shares of the company’s stock valued at $2,638,000 after purchasing an additional 56,363 shares during the period. 47.77% of the stock is owned by hedge funds and other institutional investors.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.